TABLE 1.

Main characteristics and NOS scores of studies.

Author	Nation	Cancer type	Antibody company	Sample size	Median follow-up (month)	NOS score
[6]	China	Pancreatic cancer	Santa Cruz Biotechnology	80	—	8
[24]	China	Cholangiocarcinoma	Abcam	64	—	8
[10]	China	Gastric cancer	Santa Cruz Biotechnology	65	59.6	8
[19]	China	Nasopharyngeal cancer	Santa Cruz Biotechnology	82	32.4	7
[11]	China	Breast cancer	Santa Cruz Biotechnology	60	—	8
[21]	China	Pancreatic cancer	Cell Signaling Technology	77	—	8
[18]	China	Gastric cancer	Santa Cruz Biotechnology	227	—	8
[22]	China	Hepatocellular cancer	Millipore	214	13.8	7
[23]	China	Pancreatic cancer	Cell Signaling Technology	88	—	7
[25]	China	Osteosarcomas	Cell Signaling Technology	137	—	8
[30]	China	Colorectal cancer	Abcam	80	—	8
[29]	China	Esophageal cancer	Abcam	182	—	8
[28]	Korea	Pancreatic cancer	Thermo Fisher	62	—	8
[26]	China	Astrocytoma	Thermo Fisher	98	—	8
[8]	United States	Gastric cancer	Santa Cruz Biotechnology	86	25.7	7
[9]	United States	Gastric cancer	Santa Cruz Biotechnology	86	25.9	7
[13]	Korea	Gastric cancer	Santa Cruz Biotechnology	268	—	8
[12]	United States	Glioma	Santa Cruz Biotechnology	222	—	8
[15]	China	Glioma	Cell Signaling Technology	55	—	7
[14]	China	Colorectal cancer	Abcam	86	—	8
[16]	China	Breast cancer	Bio-Rad	135	—	8
[20]	China	Pancreatic cancer	Cell Signaling Technology	88	—	8
[27]	China	Esophageal cancer	Santa Cruz Biotechnology	121	—	8
[17]	China	Nasopharyngeal carcinoma	Millipore	76	—	8

NOS, Newcastle–Ottawa Quality Assessment Scale.